Literature DB >> 9006556

Enterococcal bacteremia in the surgical intensive care unit. Does vancomycin resistance affect mortality? The Johns Hopkins SICU Study Group.

M R Mainous1, P A Lipsett, M O'Brien.   

Abstract

OBJECTIVE: To determine the incidence and mortality rate associated with nosocomial bacteremia caused by vancomycin-resistant Enterococcus in a surgical intensive care unit.
DESIGN: A retrospective study.
SETTING: The surgical intensive care unit of a large university hospital tertiary referral center. PATIENTS: All patients in the surgical intensive care unit with a documented nosocomial bacteremia between January 1, 1992, and December 31, 1994.
INTERVENTIONS: None. MAIN OUTCOME MEASURE: Mortality rate.
RESULTS: Of the 134 nosocomial bacteremic episodes, 30.6% involved enterococci; 24.4% of the enterococci were resistant to vancomycin. Patients with vancomycin-resistant enterococcal bacteremia had a significantly longer hospital stay (mean +/- SD, 28 +/- 18 vs 12 +/- 10 days; P = .005) and were more likely to have been treated with vancomycin (70% vs 10.3%; P = .001) than patients with vancomycin-sensitive enterococcal bacteremia. The mortality (41.0%) associated with enterococcal bacteremia was similar to the overall bacteremic mortality (41.7%). There was no difference in episode-specific mortality associated with vancomycin-resistant enterococci (40%) vs vancomycin-sensitive enterococci (38.7%). Of the 4 deaths associated with vancomycin-resistant enterococcal bacteremia, only 2 occurred within 14 days of the bacteremia, as did 8 of 12 deaths associated with vancomycin-sensitive enterococcal bacteremia (P = .64).
CONCLUSIONS: Enterococci were the most commonly isolated nosocomial blood-borne pathogens in the surgical intensive care unit. Nearly 25% of the enterococcal bacteremic episodes were resistant to vancomycin. Vancomycin-resistant Enterococcus is associated with a prolonged hospital stay and with vancomycin use. Nevertheless, vancomycin resistance itself does not increase the mortality rate associated with enterococcal bacteremia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9006556     DOI: 10.1001/archsurg.1997.01430250078017

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  7 in total

Review 1.  Drug resistance in intensive care units.

Authors:  W C Albrich; M Angstwurm; L Bader; R Gärtner
Journal:  Infection       Date:  1999       Impact factor: 3.553

Review 2.  Management of peritonitis in the critically ill patient.

Authors:  Carlos A Ordoñez; Juan Carlos Puyana
Journal:  Surg Clin North Am       Date:  2006-12       Impact factor: 2.741

Review 3.  Hospital epidemiology and infection control in acute-care settings.

Authors:  Emily R M Sydnor; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Surveillance strategies and impact of vancomycin-resistant enterococcal colonization and infection in critically ill patients.

Authors:  C W Hendrix; J M Hammond; S M Swoboda; W G Merz; S M Harrington; T M Perl; J D Dick; D M Borschel; P W Halczenko; R K Pelz; L E Rocco; J E Conway; R G Brower; P A Lipsett
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

5.  Incidence and risk factors of infection caused by vancomycin-resistant enterococcus colonization in neurosurgical intensive care unit patients.

Authors:  Young-Bem Se; Hyoung-Joon Chun; Hyeong-Joong Yi; Dong-Won Kim; Yong Ko; Suck-Jun Oh
Journal:  J Korean Neurosurg Soc       Date:  2009-08-31

Review 6.  Are there patients with peritonitis who require empiric therapy for enterococcus?

Authors:  S Harbarth; I Uckay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-21       Impact factor: 3.267

7.  Quinupristin-Dalfopristin.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.